We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Metabolon Collaborates with GSK for Metabolomics Research Platform

By LabMedica International staff writers
Posted on 02 Jun 2014
Print article
Metabolon, Inc. (Research Triangle Park, NC, USA), a diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline (GSK; London, UK) to provide metabolomic profiling services and to collaborate on other research projects utilizing Metabolon’s DiscoveryHD4 platform.

The collaboration will give GSK access to Metabolon’s bioinformatics tools in addition to the company’s proprietary disease ontologies, as well as visualization tools that will integrate metabolomics data with existing genomics and proteomics data.

John Ryals, Metabolon president and CEO, commented, “We are pleased to announce a collaboration with GSK. We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic ‘picture’ with the aim of yielding translatable, meaningful results. Gaps of knowledge can be bridged through the understanding metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic, and reduced risk and cost.”

Metabolomics has conducted thousands of metabolomics studies across numerous therapeutic areas and has developed expertise in metabolic pathways and targets that are involved in the onset of disease and its progression. Metabolon’s technology platforms are known for their rapid, repeatable results. Expert, credentialed biochemists interpret biologic data to provide actionable understanding into key disease metabolic processes, drug action, and patient response.

Metabolomics is a rapidly evolving field of biochemical research and discovery focused on the measurement of small molecules involved in metabolism. Metabolon’s proprietary metabolomics technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biologic processes. The company’s business uses its metabolomics technology to conduct sponsored studies for life sciences researchers in industry and academia, which provide clues into complex biochemical processes. Data from these studies are used to populate Metabolon’s large and growing metabolomic information and pathway knowledge databases, which generate new product concepts for the company’s diagnostics business.

Related Links:

Metabolon
GlaxoSmithKline


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.